Miudella is a drug owned by Sebela Womens Health Inc. It is protected by 13 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 23, 2037. Details of Miudella's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10918516 | Intrauterine device with controlled copper ion elution |
Jan, 2037
(11 years from now) | Active |
| US11207209 | Intrauterine device with retrieval thread |
Aug, 2034
(9 years from now) | Active |
| US10166141 | Intrauterine contraceptive device |
Jun, 2034
(8 years from now) | Active |
| US9265652 | Intrauterine contraceptive device |
Apr, 2034
(8 years from now) | Active |
| US10022264 | Intrauterine device with retrieval thread |
Mar, 2034
(8 years from now) | Active |
| US9610191 | Intrauterine device with retrieval thread |
Feb, 2034
(8 years from now) | Active |
| US10398588 | Intrauterine device with retrieval thread |
Feb, 2034
(8 years from now) | Active |
| US12138199 | Intrauterine device with retrieval thread |
Oct, 2033
(8 years from now) | Active |
| US9089418 | Intrauterine contraceptive device |
Apr, 2033
(7 years from now) | Active |
| US10159596 | Intrauterine contraceptive device |
Aug, 2032
(7 years from now) | Active |
| US10188546 | Intrauterine device with controlled copper ion elution |
Aug, 2032
(7 years from now) | Active |
| US11850181 | Intrauterine contraceptive device |
Aug, 2032
(7 years from now) | Active |
| US9427351 | Intrauterine contraceptive device |
Aug, 2032
(7 years from now) | Active |
FDA has granted several exclusivities to Miudella. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Miudella, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Miudella.
Exclusivity Information
Miudella holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Miudella's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 24, 2028 |
US patents provide insights into the exclusivity only within the United States, but Miudella is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Miudella's family patents as well as insights into ongoing legal events on those patents.
Miudella's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Miudella's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 23, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Miudella Generics:
There are no approved generic versions for Miudella as of now.
Alternative Brands for Miudella
There are several other brand drugs using the same active ingredient (Copper) as Miudella. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Curium |
|
About Miudella
Miudella is a drug owned by Sebela Womens Health Inc. Miudella uses Copper as an active ingredient. Miudella was launched by Sebela Womens Hlth in 2025.
Approval Date:
Miudella was approved by FDA for market use on 24 February, 2025.
Active Ingredient:
Miudella uses Copper as the active ingredient. Check out other Drugs and Companies using Copper ingredient
Dosage:
Miudella is available in system form for intrauterine use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | SYSTEM | Prescription | INTRAUTERINE |